Tirzepatide

Description

Tirzepatide is a once-weekly injectable medicine used to treat type 2 diabetes, manage chronic weight loss, and treat moderate-to-severe obstructive sleep apnoea.

Tirzepatide (the active molecule behind brand names Mounjaro and Zepbound) represents a major advancement in metabolic medicine as a dual hormone receptor agonist. Unlike earlier single-hormone treatments, tirzepatide targets two natural gut hormones involved in digestion, insulin regulation, and appetite control: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By activating both pathways simultaneously, the medication produces a synergistic effect that enhances the body’s natural metabolic processes far more effectively than single-target options.

At the core of its therapeutic function is a two-pronged mechanism governing glycemic control and weight management. To regulate blood sugar, tirzepatide stimulates the pancreas to release insulin when blood glucose spikes, while suppressing glucagon, a hormone that causes the liver to release stored glucose. Beyond blood sugar regulation, the drug works directly on the gastrointestinal tract and central nervous system to drive weight loss. It significantly delays gastric emptying—slowing down the rate at which food leaves the stomach—which physically prolongs satiety. Simultaneously, it acts on key appetite-regulating centres in the brain to reduce cravings and decrease overall caloric intake.

This dual action allows the same active compound to address multiple medical conditions under distinct brand names and indications:

• Mounjaro: Prescribed primarily for adults with type 2 diabetes to improve long-term blood sugar control (HbA1c) alongside diet and exercise.

• Zepbound: Prescribed for chronic weight management in adults with obesity or overweight conditions accompanied by weight-related health complications, including moderate-to-severe obstructive sleep apnoea.

As with most incretin-based therapies, the most frequent side effects affect the gastrointestinal system. Patients commonly experience nausea, vomiting, diarrhoea, constipation, and stomach discomfort such as cramps or bloating. These symptoms occur primarily because the medication slows digestion and changes how the gut processes food. A marked decrease in appetite is also standard, which supports weight reduction but requires patients to adjust their eating habits to ensure adequate nutritional intake. Most GI side effects are mild to moderate and tend to settle as the body adapts to the medication, particularly when dosages are increased gradually over time.

For in-vitro research and laboratory use only. Not intended for human or veterinary use. By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.